About the Company
Expanding immune system stimulation to revolutionize vaccines… That is Inovio’s (NYSE MKT: INO) quest. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease. At Inovio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.
Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
PLYMOUTH MEETING, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon® vaccine programs against tuberculosis (TB) and malaria, fully funded by more...
PLYMOUTH MEETING, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the Company will participate in the following upcoming investment conferences: BIO CEO & Investor Conference Presentation Dr. J. Joseph Kim, President & CEO...
Inovio Pharmaceuticals’ Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1...
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead Antigen Designer, have been selected as two of the “Top...